(Q37774376)

23 August 2017

1 reference

title

New quinolone antibiotics: a survey of the literature from 2005 to 2010. (English)

1 reference

23 August 2017

0 references

Jason A Wiles

1

1 reference

23 August 2017

Barton J Bradbury

series ordinal

2

1 reference

23 August 2017

Michael J Pucci

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

Expert Opinion on Therapeutic Patents

23 August 2017

published in

1 reference

23 August 2017

volume

20

1 reference

23 August 2017

issue

10

1 reference

23 August 2017

page(s)

1295-1319

1 reference

The quinolones: decades of development and use

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Antimicrobial safety: focus on fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

The 4-quinolone-3-carboxylic acid motif as a multivalent scaffold in medicinal chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Quinolone-mediated bacterial death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Quinolones: action and resistance updated

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Recent advances in bacterial topoisomerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Structure-activity relationships of the fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Sitafloxacin hydrate for bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Pharmacologic characteristics of prulifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Novel antibacterial class: a series of tetracyclic derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Different modes of action of naphthyridones in gram-positive and gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Synthesis and antibacterial activity of 7-(1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-7-yl) quinolones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Synthesis and antibacterial activity of the 4-quinolone-3-carboxylic acid derivatives having a trifluoromethyl group as a novel N-1 substituent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Metal complexes of the third-generation quinolone antimicrobial drug sparfloxacin: Structure and biological evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Nickel-quinolones interaction. Part 1 - Nickel(II) complexes with the antibacterial drug sparfloxacin: structure and biological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Nickel-quinolones interaction. Part 2--interaction of nickel(II) with the antibacterial drug oxolinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Synthesis and antitubercular activity of palladium and platinum complexes with fluoroquinolones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Isothiazolopyridones: synthesis, structure, and biological activity of a new class of antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

How many modes of action should an antibiotic have?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Dual action-based approaches to antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Hybrid molecules with a dual mode of action: dream or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Novel oxazolidinone–quinolone hybrid antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

An update on the role of nitrofurans in the management of urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Design, synthesis and in vitro antibacterial/antifungal evaluation of novel 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7(1-piperazinyl)quinoline-3-carboxylic acid derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Synthesis and activities of pyoverdin-quinolone adducts: a prospective approach to a specific Therapy against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Synthesis of citrate-ciprofloxacin conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Novel fluoroquinolones: design, synthesis, and in vivo activity in mice against Mycobacterium tuberculosis H37Rv

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Synthesis of pyrazinamide Mannich bases and its antitubercular properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Synthesis and in vitro and in vivo antimycobacterial activity of isonicotinoyl hydrazones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Synthesis, in vitro and in vivo antimycobacterial activities of diclofenac acid hydrazones and amides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Synthesis and antimycobacterial evaluation of certain fluoroquinolone derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Natural products, small molecules, and genetics in tuberculosis drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Efavirenz Mannich bases: synthesis, anti-HIV and antitubercular activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Synthesis, anti-HIV and antitubercular activities of lamivudine prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Novel approach for comparing the abilities of quinolones to restrict the emergence of resistant mutants during quinolone exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Glucose homeostasis abnormalities associated with use of gatifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Severe dysglycemia with the fluoroquinolones: a class effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.505922

Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies

21 January 2018

1 reference

7 July 2024

https://opencitations.net/index/api/v1/citations/10.1080/14756360902784425

Identifiers

DOI

10.1517/13543776.2010.505922

1 reference

23 August 2017

1 reference